GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon)are prescribed for type 2 diabetes management and, in some formulations, for weight management in adults with obesity or overweight with comorbidities
Treatment persistence has improved compared to earlier GLP-1 formulations, though discontinuation rates remain significant, often due to gastrointestinal side effects or cost concerns
The starting daily dose for the Wegovy pill is 1.5 milligrams, which can be ramped up to the maximum dose of 25 milligrams over 90 days
PMC 4588458
Fibrosis and immune cell infiltration are separate events regulated by cell-Specific receptor Notch3 expression